Abstract: A computer-implemented method of determining a position of a vehicle within a transport network comprises obtaining track geometry data indicating track geometry of at least a part of the transport network; receiving first sensor data from an inertial measurement unit mounted to the vehicle; executing a Bayesian estimation filter algorithm to predict a position of the vehicle, wherein the Bayesian estimation filter algorithm comprises a process model, the process model comprising a strapdown inertial navigation algorithm, and wherein the strapdown inertial navigation algorithm generates data indicative of the predicted position of the vehicle based at least upon the first sensor data and the track geometry data such that the predicted position of the vehicle lies on a track defined by the track geometry data; receiving second sensor data from a sensor other than an inertial measurement unit, wherein the sensor is mounted to the vehicle; executing the Bayesian estimation filter algorithm to update the predicte

Abstract: A computer-implemented method of determining a position of a vehicle 10 within a transport network comprises: obtaining track geometry data indicating track geometry of at least a part of the transport network; determining, based upon the track geometry data, that the vehicle is approaching a junction; determining, based upon the track geometry data, a plurality of route options from the junction; generating a plurality of Bayesian estimation filter algorithms each associated with a respective one of the plurality of route options and configured to estimate a position of the vehicle based upon the track geometry data indicative of the associated route option, wherein the plurality of Bayesian estimation filter algorithms are configured to output data indicative of probabilities of the vehicle taking the associated route options; monitoring the output of the plurality of Bayesian estimation filter algorithms as the vehicle passes through the junction; and determining the route option taken by the vehicle by se

Abstract: A computer-implemented method of determining a position of a vehicle within a transport network comprises obtaining track geometry data indicating track geometry of at least a part of the transport network; receiving first sensor data from an inertial measurement unit mounted to the vehicle; executing a Bayesian estimation filter algorithm to predict a position of the vehicle, wherein the Bayesian estimation filter algorithm comprises a process model, the process model comprising a strapdown inertial navigation algorithm, and wherein the strapdown inertial navigation algorithm generates data indicative of the predicted position of the vehicle based at least upon the first sensor data and the track geometry data such that the predicted position of the vehicle lies on a track defined by the track geometry data; receiving second sensor data from a sensor other than an inertial measurement unit, wherein the sensor is mounted to the vehicle; executing the Bayesian estimation filter algorithm to update the predicte

Abstract: A computer-implemented method of determining a position of a vehicle 10 within a transport network comprises: obtaining track geometry data indicating track geometry of at least a part of the transport network; determining, based upon the track geometry data, that the vehicle is approaching a junction; determining, based upon the track geometry data, a plurality of route options from the junction; generating a plurality of Bayesian estimation filter algorithms each associated with a respective one of the plurality of route options and configured to estimate a position of the vehicle based upon the track geometry data indicative of the associated route option, wherein the plurality of Bayesian estimation filter algorithms are configured to output data indicative of probabilities of the vehicle taking the associated route options; monitoring the output of the plurality of Bayesian estimation filter algorithms as the vehicle passes through the junction; and determining the route option taken by the vehicle by se

Abstract: An apparatus includes a storage device configured to store location information of multiple receivers and auxiliary data associated with a space vehicle. A motion compensation block configured to correct timing of a received signal by a receiver from a space-vehicle transmitter and to generate a motion-compensated signal having corrected timing for motions of the space-vehicle transmitter. The corrected timing is determined based on stored location information of the receiver and the auxiliary data. The frequency correction block is configured to correct a carrier frequency of the motion-compensated signal using information associated with a synch channel of the received signal and to generate a processed signal.

Abstract: An apparatus includes a storage device configured to store location information of multiple receivers and auxiliary data associated with a space vehicle. A motion compensation block configured to correct timing of a received signal by a receiver from a space-vehicle transmitter and to generate a motion-compensated signal having corrected timing for motions of the space-vehicle transmitter. The corrected timing is determined based on stored location information of the receiver and the auxiliary data. The frequency correction block is configured to correct a carrier frequency of the motion-compensated signal using information associated with a synch channel of the received signal and to generate a processed signal.

Abstract: Methods for diagnosing the presence of a disorder, such as prostate cancer, in a subject are provided, such methods including detecting the relative frequency of expression of RNA biomarkers in a biological sample obtained from the subject, for example, using NGS technology and comparing the relative levels of expression with predetermined threshold levels. Levels of expression of at least two of the RNA biomarkers that are above or below the predetermined threshold levels are indicative of the presence of prostate cancer in the subject. Also provided is a method for preparing a reference standard for quantitating the relative frequency of expression of RNA biomarkers in a biological sample obtained from the subject with a prostate cancer lesion using NGS technology.

Abstract: Methods for diagnosing the presence of a disorder, such as prostate cancer, in a subject are provided, such methods including detecting the relative frequency of expression of RNA biomarkers in a biological sample obtained from the subject, for example, using NGS technology and comparing the relative levels of expression with predetermined threshold levels. Levels of expression of at least two of the RNA biomarkers that are above or below the predetermined threshold levels are indicative of the presence of prostate cancer in the subject. Also provided is a method for preparing a reference standard for quantitating the relative frequency of expression of RNA biomarkers in a biological sample obtained from the subject with a prostate cancer lesion using NGS technology.

Abstract: Methods for diagnosing the presence of a disorder, such as prostate cancer, in a subject are provided, such methods including detecting the relative frequency of expression of RNA biomarkers in a biological sample obtained from the subject, for example, using NGS technology and comparing the relative levels of expression with predetermined threshold levels. Levels of expression of at least two of the RNA biomarkers that are above or below the predetermined threshold levels are indicative of the presence of prostate cancer in the subject. Also provided is a method for preparing a reference standard for quantitating the relative frequency of expression of RNA biomarkers in a biological sample obtained from the subject with a prostate cancer lesion using NGS technology.

Abstract: Methods for diagnosing the presence of a disorder, such as prostate cancer, in a subject are provided, such methods including detecting the relative frequency of expression of RNA biomarkers in a biological sample obtained from the subject using NGS technology and comparing the relative levels of expression with predetermined threshold levels. Levels of expression of at least two of the RNA biomarkers that are above the predetermined threshold levels are indicative of the presence of prostate cancer in the subject. Also provided is a method for preparing a reference standard for quantitating the relative frequency of expression of RNA biomarkers in a biological sample obtained from the subject with a prostate cancer lesion using, for example, NGS technology.

Abstract: Methods for monitoring, and determining the efficacy of, a treatment for prostate cancer in a subject are provided, such methods including detecting the levels of expression of multiple polypeptide biomarkers in biological samples obtained from the subject prior to, and during, a course of treatment. Specific patterns of changes in the expression of the polypeptide biomarkers are indicative of the effectiveness of the treatment in the subject.

Abstract: Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including detecting the levels of expression of multiple polypeptide biomarkers in a biological sample obtained from the subject and comparing the levels of expression with predetermined threshold levels. Levels of expression of at least two of the polypeptide markers that are above the predetermined threshold levels are indicative of the presence of prostate cancer in the subject. Determination of the expression levels of specific combinations of biomarkers can also be used to determine the type and/or stage of prostate cancer.

Abstract: Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including detecting the levels of expression of multiple polypeptide biomarkers in a biological sample obtained from the subject and comparing the levels of expression with predetermined threshold levels. Levels of expression of at least two of the polypeptide markers that are above the predetermined threshold levels are indicative of the presence of prostate cancer in the subject. Determination of the expression levels of specific combinations of biomarkers can also be used to determine the type and/or stage of prostate cancer.

Abstract: Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including detecting the levels of expression of multiple polypeptide biomarkers in a biological sample obtained from the subject and comparing the levels of expression with predetermined threshold levels. Levels of expression of at least two of the polypeptide markers that are above the predetermined threshold levels are indicative of the presence of prostate cancer in the subject. Determination of the expression levels of specific combinations of biomarkers can also be used to determine the type and/or stage of prostate cancer.

Abstract: Methods for monitoring, and determining the efficacy of, a treatment for prostate cancer in a subject are provided, such methods including detecting the levels of expression of multiple polypeptide biomarkers in biological samples obtained from the subject prior to, and during, a course of treatment. Specific patterns of changes in the expression of the polypeptide biomarkers are indicative of the effectiveness of the treatment in the subject.

Abstract: The present disclosure provides methods for selecting a treatment composition, or therapy, for the treatment of a cancer, such as prostate or breast cancer, in a patient wherein the treatment composition includes administering a combination of at least two components selected from two different classes of compounds. Methods for treating a patient using the selected treatment composition are also provided, together with methods for monitoring the efficacy of the treatment composition during a treatment period.

Abstract: Methods for diagnosing the presence of a disorder, such as prostate cancer, in a subject are provided, such methods including detecting the relative frequency of expression of RNA biomarkers in a biological sample obtained from the subject using RNA-seq technology and comparing the relative levels of expression with predetermined threshold levels. Levels of expression of at least two of the RNA biomarkers that are above the predetermined threshold levels are indicative of the presence of prostate cancer in the subject.

Abstract: A continuous flow wood processing technology for extracting lignin from woody plant material and converting the delignified cellulosic residue to crude bio-oils is provided. Wood is chipped before processing starts and fed into a lignin extractor. The lignin extractor uses ethanol at high temperatures to dissolve the lignin with counter current material contactors. The ethanol containing dissolved lignin is removed from the lignin extractor, the dissolved lignin recovered, the ethanol and residual heat being recycled into the lignin extractor. The delignified cellulosic pulp is removed from the lignin extractor and subjected to a milling operation to convert the pulp into a smooth sludge for entry to a bio-convertor by a super critical water process. The product from this convertor is hydrocarbon sludge with a principal component being a kerogen. In a separate process crude oil is extracted from this sludge and the residue is prepared as a high phosphate Fertilizer.

Abstract: Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including detecting the levels of expression of multiple polypeptide biomarkers in a biological sample obtained from the subject and comparing the levels of expression with predetermined threshold levels. Levels of expression of at least two of the polypeptide markers that are above the predetermined threshold levels are indicative of the presence of prostate cancer in the subject. Determination of the expression levels of specific combinations of biomarkers can also be used to determine the type and/or stage of prostate cancer.

Abstract: Methods for monitoring, and determining the efficacy of, a treatment for prostate cancer in a subject are provided, such methods including detecting the levels of expression of multiple polypeptide biomarkers in biological samples obtained from the subject prior to, and during, a course of treatment. Specific patterns of changes in the expression of the polypeptide biomarkers are indicative of the effectiveness of the treatment in the subject.